Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay

Official Title

Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Cancer Panel

Summary:

Currently, publicly funded standard of care testing in Ontario for stage IV lung cancer patients uses individual gene tests to look for mutations in the EGFR and ALK genes. This testing broadens treatment options for patients, however there are other gene mutations with corresponding targeted treatments that are not routinely tested for. This study will evaluate the utility and added value of using a next generation sequencing (NGS) panel, the Oncomine Comprehensive Assay v3, to profile stage IV lung cancer patients.

Trial Description

Primary Outcome:

  • Incremental actionable targets
  • Number of clinical trial opportunities
Secondary Outcome:
  • Test turnaround time
  • Financial feasibility
  • Patient willingness-to-pay

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society